市場調查報告書
商品編碼
1020958

新型疫苗輸送系統市場:各輸送模式(皮內,皮下,肌肉內,其他),各設備(注射器,無針頭注射系統,其他):全球機會分析與產業預測(2021∼2030年)

Novel Vaccine Delivery Systems Market by Delivery Mode (Intradermal, Subcutaneous, Intramuscular, and Other), Device (Syringe, Needle-Free Injection System, and Others): Global Opportunity Analysis and Industry Forecast, 2021-2030.

出版日期: | 出版商: Allied Market Research | 英文 208 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球新型疫苗輸送系統的市場規模2020年是50億3千萬美金。

該市場,預計從2021年到2030年以10.8%的年複合成長率擴大,至2030年達到144億3,700萬美元。

推動新型疫苗遞送系統市場成長的驅動因素,包括不斷成長的免疫計劃及其覆蓋範圍的擴大,政府對各種免疫計劃的支持不斷增加,以及對研發新疫苗的投資。此外,用於治療各種疾病的新型疫苗的開發進一步推動了市場的成長。然而,安全注射器的高成本和負擔不起以及藥物輸送的替代模式限制了市場的成長。

本報告提供新型疫苗輸送系統市場相關調查,市場概要,以及輸送模式,各設備,各地區的趨勢,及加入此市場的主要企業簡介等資訊。

目錄

第1章 簡介

第2章 摘要整理

第3章 市場形勢

  • 市場定義和範圍
  • 主要調查結果
    • 主要的投資口袋
    • 主要的成功策略
  • 波特的五力分析
  • 最高參與者的定位,2020年
  • 市場動態
    • 促進因素
      • 免疫化計劃的擴大與其目標範圍的擴大
      • 政府的輔助和投資增加
      • 新疫苗的開發
    • 阻礙因素
      • 安全性注射器的成本高和合理價格
      • 藥物輸送的替代方式
    • 市場機會
      • 在新興經濟國安全性注射器的必要性高漲
      • 對COVID19疫苗的FDA認證
    • 影響分析
  • Covid-19新型疫苗輸送系統對市場的影響分析

第4章 新型疫苗輸送系統市場:各輸送模式

  • 概要
    • 市場規模與預測
  • 皮內
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測:各地區
    • 市場分析:各國
  • 皮下
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測
    • 市場分析:各國
  • 肌肉內
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測
    • 市場分析:各國
  • 其他
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測
    • 市場分析:各國

第5章 新型疫苗輸送系統:各設備

  • 概要
    • 市場規模與預測
  • 注射器
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測:各地區
    • 市場分析:各國
    • 市場規模與預測:各類型
    • 一般的注射器
    • 智慧注射器
      • 市場規模與預測
      • 智慧注射器:各類型
      • 智慧注射器,市場規模及預測:各類型
  • 無針頭注射系統
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測
    • 市場分析:各國
    • 市場規模與預測:各類型
    • 彈簧為基礎的注射器系統
      • 市場規模與預測
    • 氣體推動/空氣動力注射器系統
      • 市場規模與預測
    • 其他
      • 市場規模與預測
  • 其他
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測
    • 市場分析:各國

第6章 新型疫苗輸送系統:各地區

  • 概要
    • 市場規模與預測
  • 北美
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測:各國
      • 美國
      • 加拿大
      • 墨西哥
    • 北美的市場規模與預測:各輸送模式
    • 北美的市場規模與預測:各設備
  • 歐洲
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測:各國
      • 德國
      • 法國
      • 英國
      • 義大利
      • 西班牙
      • 其他
    • 歐洲的市場規模與預測:各輸送模式
    • 歐洲的市場規模與預測:各設備
  • 亞太地區
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測:各國
      • 日本
      • 中國
      • 澳洲
      • 印度
      • 韓國
      • 其他
    • 亞太地區市場規模與預測:各輸送模式
    • 亞太地區市場規模與預測:各設備
  • LAMEA
    • 主要的市場趨勢,成長要素,及機會
    • 市場規模與預測:各國
      • 巴西
      • 沙烏地阿拉伯
      • 南非
      • 其他
    • LAMEA的市場規模與預測:各輸送模式
    • LAMEA的市場規模與預測:各設備

第7章 企業簡介

  • CAPITAL PARTNERS, LLC(KINDEVA DRUG DELIVERY)
  • BECTON, DICKINSON, AND COMPANY
  • CARL ZEISS FOUNDATION(SCHOTT AG)
  • GERRESHEIMER AG
  • GURNET POINT CAPITAL(CORIUM INTERNATIONAL INC.)
  • INOVIO PHARMACEUTICALS, INC.(BIOJECT MEDICAL TECHNOLOGIES)
  • PHARMAJET, INC.
  • RETRACTABLE TECHNOLOGIES, INC.
  • TERUMO CORPORATION
  • VAXXAS PTY LTD
目錄
Product Code: A11784

The global novel vaccine delivery systems market was valued at $5,030 million in 2020 and is projected to reach $14,437 million by 2030 registering a CAGR of 10.8% from 2021 to 2030.

Vaccines, often known as immunizations, inject a weakened form of a pathogen into a person to cause the body to produce antibodies or immunity against the illness. A number of diseases with significant mortality rates, such as polio and smallpox, have been eliminated owing to effective vaccinations. Vaccinations are used in a variety of regional disease-prevention programs since they serve such an important role in maintaining people's long-term health in different countries. The need for immunizations has risen in recent years as the frequency of viral and bacterial infectious illnesses has increased. Vaccines are essentially administered to people of different age groups, which strengthen their immune system throughout lifetime and offers protection against different types of infectious diseases. The term "novel vaccine delivery" refers to the systems that are used to safely deliver an active medicinal component into the body.

The driving factors that drive the novel vaccine delivery systems market growth include, growing immunization programs & their increasing coverage, increasing government support for various immunization programs and investment for R & D to develop new vaccines. In addition, development of novel vaccines for treating various diseases further boosts the growth of the market. However, high cost and unaffordability of safety syringes as well as alternative modes of drug delivery restrains the growth of the market. In contrast, rise in need for safety syringes in emerging economies and FDA approval to COVID 19 Vaccine create lucrative opportunities for the novel vaccine delivery system.

The global novel vaccine delivery systems market is segmented into delivery mode, device and region. On the basis of delivery mode, the market is categorized into intradermal, subcutaneous, intramuscular, and other. By device, it is classified into syringe, needle-free injection system, and others. Syringe again classified into conventional syringe and smart syringe. Smart syringe again segmented into active safety syringes, passive safety syringes, and auto disable syringes. Needle-free injection system again classified into spring-based injector systems, gas propelled/air forced injector system, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

  • The study provides an in-depth analysis of the global novel vaccine delivery systems market along with the current trends and future estimations to explain the imminent investment pockets.
  • A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
  • Comprehensive quantitative analysis of the industry from 2020 to 2030 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the key segments of the industry helps to understand the application and products of novel vaccine delivery systems used across the globe.
  • Key market players and their strategies have been analyzed to understand the competitive outlook of the market.

KEY MARKET SEGMENTS

By Delivery Mode

  • Intradermal
  • Subcutaneous
  • Intramuscular
  • Other

By Device

  • Syringe
  • Conventional Syringe
  • Smart Syringe
  • Active Safety Syringes
  • Passive Safety Syringes
  • Auto Disable Syringes
  • Needle free injection System
  • Spring-based Injector Systems
  • Gas Propelled/Air Forced Injector Systems
  • Others
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • LIST OF KEY PLAYERS PROFILED IN THE REPORT
  • Altaris Capital Partners, LLC (Kindeva Drug Delivery)
  • Becton, Dickinson, and Company
  • Carl Zeiss Foundation (Schott AG)
  • Gerresheimer AG
  • Gurnet Point Capital (Corium International Inc.)
  • Inovio Pharmaceuticals, Inc. (Bioject Medical Technologies)
  • PharmaJet, Inc.
  • Retractable Technologies, Inc.
  • Terumo Corporation
  • VAXXAS Pty Ltd.

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key Benefits for Stakeholders
  • 1.3.Key market segments
    • 1.3.1.List of key players profiled in the report
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET LANDSCAPE

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Porter's five force analysis
  • 3.4.Top player positioning, 2020
  • 3.5.Market dynamics
    • 3.5.1.Drivers
      • 3.5.1.1.Growing immunization programs & their increasing coverage
      • 3.5.1.2.Increasing government support and investment
      • 3.5.1.3.Development of novel vaccines
    • 3.5.2.Restraints
      • 3.5.2.1.High cost and unaffordability of safety syringes
      • 3.5.2.2.Alternative modes of drug delivery
    • 3.5.3.Opportunities
      • 3.5.3.1.Rise in need for safety syringes in emerging economies
      • 3.5.3.2.FDA approval to COVID 19 Vaccine
    • 3.5.4.Impact analysis
  • 3.6.Covid-19 Impact analysis on novel vaccine delivery system market

CHAPTER 4:NOVEL VACCINE DELIVERY SYSTEMS MARKET, BY DELIVERY MODE

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.Intradermal
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Subcutaneous
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast
    • 4.3.3.Market analysis, by country
  • 4.4.Intramuscular
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast
    • 4.4.3.Market analysis, by country
  • 4.5.Others
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast
    • 4.5.3.Market analysis, by country

CHAPTER 5:NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Syringe
    • 5.2.1.Key market trends, growth factors, and opportunities
    • 5.2.2.Market size and forecast, by region
    • 5.2.3.Market analysis, by country
    • 5.2.4.Market size and forecast, by type
    • 5.2.5.General Syringe
    • 5.2.6.Smart Syringe
      • 5.2.6.1.Market size and forecast
      • 5.2.6.2.Smart Syringe, By type
      • 5.2.6.3.smart syringe, market size and forecast, by type
      • 5.2.6.3.1.Auto disable syringes, market size and forecast
      • 5.2.6.3.2.Active safety syringes, market size and forecast
      • 5.2.6.3.3.Passive safety syringes, market size and forecast
  • 5.3.Needle-free Injection System
    • 5.3.1.Key market trends, growth factors, and opportunities
    • 5.3.2.Market size and forecast
    • 5.3.3.Market analysis, by country
    • 5.3.4.Market size and forecast, by type
    • 5.3.5.Spring-based Injector Systems
      • 5.3.5.1.Market size and forecast
    • 5.3.6.Gas Propelled/Air Forced Injector Systems
      • 5.3.6.1.Market size and forecast
    • 5.3.7.Others
      • 5.3.7.1.Market size and forecast
  • 5.4.Others
    • 5.4.1.Key market trends, growth factors, and opportunities
    • 5.4.2.Market size and forecast
    • 5.4.3.Market analysis, by country

CHAPTER 6:NOVEL VACCINE DELIVERY SYSTEM, BY REGION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.North America
    • 6.2.1.Key market trends, growth factors, and opportunities
    • 6.2.2.Market size and forecast, by country
      • 6.2.2.1.U.S.
      • 6.2.2.1.1.U.S. Novel vaccine delivery system, by delivery mode
      • 6.2.2.1.2.U.S. Novel vaccine delivery system, by device
      • 6.2.2.2.Canada
      • 6.2.2.2.1.Canada Novel vaccine delivery system, by delivery mode
      • 6.2.2.2.2.Canada Novel vaccine delivery system, by device
      • 6.2.2.3.Mexico
      • 6.2.2.3.1.Mexico Novel vaccine delivery system, by delivery mode
      • 6.2.2.3.2.Mexico Novel vaccine delivery system, by device
    • 6.2.3.North America market size and forecast, by delivery mode
    • 6.2.4.North America market size and forecast, by device
  • 6.3.Europe
    • 6.3.1.Key market trends, growth factors, and opportunities
    • 6.3.2.Market size and forecast, by country
      • 6.3.2.1.Germany
      • 6.3.2.1.1.Germany Novel vaccine delivery system, by delivery mode
      • 6.3.2.1.2.Germany Novel vaccine delivery system, by device
      • 6.3.2.2.France
      • 6.3.2.2.1.France Novel vaccine delivery system, by delivery mode
      • 6.3.2.2.2.France Novel vaccine delivery system, by device
      • 6.3.2.3.UK
      • 6.3.2.3.1.UK Novel vaccine delivery system, by delivery mode
      • 6.3.2.3.2.UK Novel vaccine delivery system, by device
      • 6.3.2.4.Italy
      • 6.3.2.4.1.Italy Novel vaccine delivery system, by delivery mode
      • 6.3.2.4.2.Italy Novel vaccine delivery system, by device
      • 6.3.2.5.Spain
      • 6.3.2.5.1.Spain Novel vaccine delivery system, by delivery mode
      • 6.3.2.5.2.Spain Novel vaccine delivery system, by device
      • 6.3.2.6.Rest of Europe
      • 6.3.2.6.1.Rest of Europe Novel vaccine delivery system, by delivery mode
      • 6.3.2.6.2.Rest of Europe Novel vaccine delivery system, by device
    • 6.3.3.Europe market size and forecast, by delivery mode
    • 6.3.4.Europe market size and forecast, by device
  • 6.4.Asia-Pacific
    • 6.4.1.Key market trends, growth factors, and opportunities
    • 6.4.2.Market size and forecast, by country
      • 6.4.2.1.Japan
      • 6.4.2.1.1.Japan Novel vaccine delivery system, by delivery mode
      • 6.4.2.1.2.Japan Novel vaccine delivery system, by device
      • 6.4.2.2.China
      • 6.4.2.2.1.China Novel vaccine delivery system, by delivery mode
      • 6.4.2.2.2.China Novel vaccine delivery system, by device
      • 6.4.2.3.Australia
      • 6.4.2.3.1.Australia Novel vaccine delivery system, by delivery mode
      • 6.4.2.3.2.Australia Novel vaccine delivery system, by device
      • 6.4.2.4.India
      • 6.4.2.4.1.India Novel vaccine delivery system, by delivery mode
      • 6.4.2.4.2.India Novel vaccine delivery system, by device
      • 6.4.2.5.South Korea
      • 6.4.2.5.1.South Korea Novel vaccine delivery system, by delivery mode
      • 6.4.2.5.2.South Korea Novel vaccine delivery system, by device
      • 6.4.2.6.Rest of Asia-Pacific
      • 6.4.2.6.1.Rest of Asia-Pacific Novel vaccine delivery system, by delivery mode
      • 6.4.2.6.2.Rest of Asia-Pacific Novel vaccine delivery system, by device
    • 6.4.3.Asia-Pacific market size and forecast, by delivery mode
    • 6.4.4.Asia-Pacific market size and forecast, by device
  • 6.5.LAMEA
    • 6.5.1.Key market trends, growth factors, and opportunities
    • 6.5.2.Market size and forecast, by country
      • 6.5.2.1.Brazil
      • 6.5.2.1.1.Brazil Novel vaccine delivery system, by delivery mode
      • 6.5.2.1.2.Brazil Novel vaccine delivery system, by device
      • 6.5.2.2.Saudi Arabia
      • 6.5.2.2.1.Saudi Arabia Novel vaccine delivery system, by delivery mode
      • 6.5.2.2.2.Saudi Arabia Novel vaccine delivery system, by device
      • 6.5.2.3.South Africa
      • 6.5.2.3.1.South Africa Novel vaccine delivery system, by delivery mode
      • 6.5.2.3.2.South Africa Novel vaccine delivery system, by device
      • 6.5.2.4.Rest of LAMEA
      • 6.5.2.4.1.Rest of LAMEA Novel vaccine delivery system, by delivery mode
      • 6.5.2.4.2.Rest of LAMEA Novel vaccine delivery system, by device
    • 6.5.3.LAMEA market size and forecast, by delivery mode
    • 6.5.4.LAMEA market size and forecast, by device

CHAPTER 7:COMPANY PROFILES

  • 7.1.CAPITAL PARTNERS, LLC (KINDEVA DRUG DELIVERY)
    • 7.1.1.Company overview
    • 7.1.2.Company snapshot
    • 7.1.3.Operating business segments
    • 7.1.4.Product portfolio
    • 7.1.5.Business performance
  • 7.2.BECTON, DICKINSON, AND COMPANY
    • 7.2.1.Company overview
    • 7.2.2.Company snapshot
    • 7.2.3.Operating business segments
    • 7.2.4.Product portfolio
    • 7.2.5.Business performance.
  • 7.3.CARL ZEISS FOUNDATION (SCHOTT AG)
    • 7.3.1.Company overview
    • 7.3.2.Company snapshot
    • 7.3.3.Operating business segments
    • 7.3.4.Product portfolio
    • 7.3.5.Business performance
  • 7.4.GERRESHEIMER AG
    • 7.4.1.Company overview
    • 7.4.2.Company snapshot
    • 7.4.3.Operating business segments
    • 7.4.4.Product portfolio
    • 7.4.5.Business performance
  • 7.5.GURNET POINT CAPITAL (CORIUM INTERNATIONAL INC.)
    • 7.5.1.Company overview
    • 7.5.2.Company snapshot
    • 7.5.3.Operating business segments
    • 7.5.4.Product portfolio
    • 7.5.5.Business performance.
  • 7.6.INOVIO PHARMACEUTICALS, INC. (BIOJECT MEDICAL TECHNOLOGIES)
    • 7.6.1.Company overview
    • 7.6.2.Company snapshot
    • 7.6.3.Operating business segments
    • 7.6.4.Product portfolio
    • 7.6.5.Business performance
  • 7.7.PHARMAJET, INC.
    • 7.7.1.Company overview
    • 7.7.2.Company snapshot
    • 7.7.3.Operating business segments
    • 7.7.4.Product portfolio
    • 7.7.5.Business performance
  • 7.8.RETRACTABLE TECHNOLOGIES, INC.
    • 7.8.1.Company overview
    • 7.8.2.Company snapshot
    • 7.8.3.Operating business segments
    • 7.8.4.Product portfolio
    • 7.8.5.Business performance
  • 7.9.TERUMO CORPORATION
    • 7.9.1.Company overview
    • 7.9.2.Company snapshot
    • 7.9.3.Operating business segments
    • 7.9.4.Product portfolio
    • 7.9.5.Business performance
  • 7.10.VAXXAS PTY LTD
    • 7.10.1.Company overview
    • 7.10.2.Company snapshot
    • 7.10.3.Operating business segments
    • 7.10.4.Product portfolio
    • 7.10.5.Business performance.
    • 7.10.6.Key strategic moves and developments

LIST OF TABLES

  • TABLE 01.GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET, BY DELIVERY MODE, 2020-2030($MILLION)
  • TABLE 02.INTRAMUSCULAR NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 03.INTRADERMAL NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 04.SUBCUTANEOUS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 05.OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 06.GLOBAL NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030($MILLION)
  • TABLE 07.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY REGION, 2020-2030($MILLION)
  • TABLE 08.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 09.NEEDLE FREE INJECTION SYSTEM NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 10.NOVEL VACCINE DELIVERY SYSTEM MARKET FOR NEEDLE FREE INJECTION SYSTEM, BY TYPE, 2020-2030, ($MILLION)
  • TABLE 11.OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 12.NOVEL VACCINE DELIVERY SYSTEM, BY REGION, 2020-2030($MILLION)
  • TABLE 13.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 14.U.S. NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 15.U.S. NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 16.CANADA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 17.CANADA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 18.MEXICO NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 19.MEXICO NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 20.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 21.NORTH AMERICA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 22.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 23.GERMANY NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 24.GERMANY NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 25.FRANCE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 26.FRANCE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 27.UK NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 28.UK NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 29.ITALY NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 30.ITALY NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 31.SPAIN NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 32.SPAIN NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 33.REST OF EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 34.REST OF EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 35.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 36.EUROPE NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 37.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 38.JAPAN NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 39.JAPAN NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 40.CHINA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 41.CHINA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 42.AUSTRALIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 43.AUSTRALIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 44.INDIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 45.INDIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 46.SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 47.SOUTH KOREA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 48.REST OF ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 49.REST OF ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 50.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 51.ASIA-PACIFIC NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 52.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020-2030($MILLION)
  • TABLE 53.BRAZIL NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 54.BRAZIL NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 55.SAUDI ARABIA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 56.SAUDI ARABIA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 57.SOUTH AFRICA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 58.SOUTH AFRICA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 59.REST OF LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 60.REST OF LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 61.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DELIVERY MODE, 2020-2030
  • TABLE 62.LAMEA NOVEL VACCINE DELIVERY SYSTEM, BY DEVICE, 2020-2030
  • TABLE 63.ALTARIS: COMPANY SNAPSHOT
  • TABLE 64.ALTARIS: PRODUCT PORTFOLIO
  • TABLE 65.BD: COMPANY SNAPSHOT
  • TABLE 66.BD: OPERATING SEGMENTS
  • TABLE 67.BD: PRODUCT PORTFOLIO
  • TABLE 68.BD: NET SALES, 2018-2020 ($MILLION)
  • TABLE 69.BD: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • TABLE 70.BD: REVENUE SHARE, BY REGION, 2020 (%)
  • TABLE 71.CARL ZEISS: COMPANY SNAPSHOT
  • TABLE 72.CARL ZEISS: PRODUCT PORTFOLIO
  • TABLE 73.GERRESHEIMER: COMPANY SNAPSHOT
  • TABLE 74.GERRESHEIMER: OPERATING SEGMENTS
  • TABLE 75.GERRESHEIMER: PRODUCT PORTFOLIO
  • TABLE 76.GERRESHEIMER: NET SALES, 2018-2020 ($MILLION)
  • TABLE 77.GERRESHEIMER: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • TABLE 78.GERRESHEIMER: REVENUE SHARE, BY REGION, 2020 (%)
  • TABLE 79.GURNET POINT: COMPANY SNAPSHOT
  • TABLE 80.GURNET POINT: PRODUCT PORTFOLIO
  • TABLE 81.INOVIO: COMPANY SNAPSHOT
  • TABLE 82.INOVIO: PRODUCT PORTFOLIO
  • TABLE 83.INOVIO: NET SALES, 2018-2020 ($MILLION)
  • TABLE 84.PHARMAJET: COMPANY SNAPSHOT
  • TABLE 85.PHARMAJET: OPERATING SEGMENT
  • TABLE 86.PHARMAJET: PRODUCT PORTFOLIO
  • TABLE 87.RETRACTABLE TECHNOLOGIES: COMPANY SNAPSHOT
  • TABLE 88.RETRACTABLE: PRODUCT PORTFOLIO
  • TABLE 89.RETRACTABLE TECHNOLOGIES: NET SALES, 2018-2020 ($MILLION)
  • TABLE 90.RETRACTABLE TECHNOLOGIES: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • TABLE 91.RETRACTABLE TECHNOLOGIES: REVENUE SHARE, BY REGION, 2020 (%)
  • TABLE 92.TERUMO: COMPANY SNAPSHOT
  • TABLE 93.TERUMO: OPERATING SEGMENTS
  • TABLE 94.TERUMO: PRODUCT PORTFOLIO
  • TABLE 95.TERUMO: NET SALES, 2018-2020 ($MILLION)
  • TABLE 96.TERUMO: REVENUE SHARE, BY SEGMENT, 2020 (%)
  • TABLE 97.TERUMO: REVENUE SHARE, BY REGION, 2020 (%)
  • TABLE 98.VAXXAS: COMPANY SNAPSHOT
  • TABLE 99.VAXXAS: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.GLOBAL NOVEL VACCINE DELIVERY SYSTEMS MARKET SEGMENTATION
  • FIGURE 02.TOP INVESTMENT POCKETS
  • FIGURE 03.TOP WINNING STRATEGIES, BY YEAR, 2018-2020
  • FIGURE 04.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2018-2020
  • FIGURE 05.TOP WINNING STRATEGIES, BY COMPANY, 2018-2020
  • FIGURE 01.MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 02.MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 03.MODERATE THREAT OF SUBSTITUTES
  • FIGURE 04.MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 05.HIGH INTENSITY OF RIVALRY
  • FIGURE 06.TOP PLAYER POSITIONING, 2020
  • FIGURE 07.IMPACT ANALYSIS
  • FIGURE 08.COMPARATIVE ANALYSIS OF INTRAMUSCULAR NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 09.COMPARATIVE ANALYSIS OF INTRADERMAL NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 10.COMPARATIVE ANALYSIS OF SUBCUTANEOUS NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 11.COMPARATIVE ANALYSIS OF OTHER NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 12.COMPARATIVE ANALYSIS OF NOVEL VACCINE DELIVERY SYSTEM MARKET FOR SYRINGE, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 13.CONVENTIONAL SYRINGE MARKET, 2020-2030, ($MILLION)
  • FIGURE 14.SMART SYRINGE MARKET, 2020-2030, ($MILLION)
  • FIGURE 15.GLOBAL SMART SYRINGE MARKET, BY TYPE, 2020-2030 ($MILLION)
  • FIGURE 16.GLOBAL SMART SYRINGE MARKET FOR ACTIVE SAFETY SYRINGES, BY TYPE 2020-2030 ($MILLION)
  • FIGURE 17.GLOBAL SMART SYRINGE MARKET FOR PASSIVE SAFETY SYRINGES, BY TYPE, 2020-2030 ($MILLION)
  • FIGURE 18.GLOBAL SMART SYRINGE MARKET FOR AUTO DISABLE SYRINGES, BY TYPE 2020-2030 ($MILLION)
  • FIGURE 19.COMPARATIVE ANALYSIS OF NEEDLE FREE INJECTION SYSTEM NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)
  • FIGURE 20.SPRING-BASED INJECTOR SYSTEMS MARKET, 2020-2030, ($MILLION)
  • FIGURE 21.GAS PROPELLED/AIR FORCED INJECTOR SYSTEMS MARKET, 2020-2030, ($MILLION)
  • FIGURE 22.OTHERS MARKET, 2020-2030, ($MILLION)
  • FIGURE 23.COMPARATIVE ANALYSIS OF OTHERS NOVEL VACCINE DELIVERY SYSTEM, BY COUNTRY, 2020 & 2030 ($MILLION)